Boston Scientific (BSX) announced the close of its acquisition of Silk Road Medical (SILK). The acquisition includes a purchase price of $27.50 per share, reflecting an enterprise value of approximately $1.18B. The impact to Boston Scientific adjusted earnings per share is expected to be immaterial in 2024 and 2025, and accretive thereafter. The impact to GAAP earnings per share is expected to be less accretive, or dilutive, as the case may be, due to amortization expense and acquisition-related net charges.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific: FDA approves expanded indication of INGEVITY+ Pacing Leads
- Boston Scientific participates in a conference call with Piper Sandler
- Election 2024: Where To Put Your Money Ahead of the Vote
- Boston Scientific price target raised to $94 from $91 at Raymond James
- Boston Scientific put volume heavy and directionally bearish